Sai Parenteral's Ltd., incorporated in 2001, is a pharmaceutical formulations company engaged in research, development, and manufacturing of a wide range of medicines. The company operates through two main business segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) services for domestic and international pharmaceutical companies. The company offers products across multiple therapeutic segments such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory care, antibiotics, gastroenterology, vitamins and supplements, analgesics, and dermatology. These medicines are available in several dosage forms including injectables, tablets, capsules, liquid orals, and ointments. Sai Parenteral's serves a large customer base that includes government agencies, pharmaceutical companies, hospitals, and distribution partners across India. The company also expanded its export business in FY 2023 after acquiring internationally accredited manufacturing facilities in Hyderabad, Telangana. Through these facilities, it now supplies products to regulated and semi-regulated markets such as Australia, New Zealand, Southeast Asia, the Middle East, and Africa.

The company operates five manufacturing facilities in India, four of which are located in Hyderabad, Telangana. These include GMP-compliant injectable units, WHO-GMP facilities, and internationally accredited production plants. Its subsidiary, Revat Laboratories, operates a GMP-certified manufacturing unit in Ongole, Andhra Pradesh. As of December 31, 2025, the company had 298 full-time employees supporting its operations.